Study of combination therapy before surgery for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two drugs given before surgery to treat early-stage triple-negative breast cancer that is PD-L1 positive. The goal is to see if the combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- You have been diagnosed with early-stage triple-negative breast cancer that is PD-L1 positive.
- You have not had any prior treatment for breast cancer, such as chemotherapy or radiation.
- Your tumor is at a certain size and lymph node stage (T1c-T2, N0-1 or T1a-T1b, N1).
- You are in good overall health with adequate organ function.
- You are not pregnant or breastfeeding and agree to use contraception during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Sacituzumab Govitecan and Tislelizumab) given before surgery to shrink early-stage triple-negative breast cancer. The goal is to see if a lower dose of treatment can still work well.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests a combination of two drugs (serplulimab and trastuzumab rezetecan) given before surgery to shrink tumors in people with early-stage triple-negative breast cancer. The goal is to see if this treatment helps remove more cancer cells before the main surgery.
This trial tests whether adding a new immunotherapy drug (adebrelimab) and a targeted therapy (T-DXd) to standard chemotherapy works better than chemotherapy alone for early-stage HR+/HER2-low breast cancer before surgery. It aims to shrink the tumor and reduce the chance of cancer coming back.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This trial tests a combination of two drugs (SHR-A1811 and Adebrelimab) given before surgery to women with a certain type of breast cancer that is hormone receptor (HR) negative or low and HER2 low. The goal is to see if this treatment can shrink the tumor before surgery.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.